Molecular Precision. Therapeutic Transformation.
Neologicals is a proprietary ligand-receptor targeting platform engineered to deliver potent therapeutic payloads with sub-nanomolar precision — selectively to diseased tissue, sparing healthy cells.
A Fundamentally Different Approach to Drug Delivery
Conventional therapeutics flood the body with cytotoxic agents, relying on the tumor's faster growth rate to achieve a therapeutic window. Neologicals inverts this paradigm. By engineering high-affinity ligands that bind with extraordinary selectivity to receptors overexpressed on diseased cells, we achieve active targeting — not passive accumulation. The result is a dramatically expanded therapeutic index, enabling doses and efficacy profiles previously unattainable.
Four Steps to Precision Delivery
Neologicals begins with deep transcriptomic and proteomic profiling of diseased tissue versus healthy tissue. Proprietary bioinformatics pipelines identify receptor overexpression signatures — molecular addresses unique to the pathological cell population. Targets are validated across patient-derived cell lines and primary tissue samples before ligand development begins.
Using structure-guided design and iterative affinity maturation, our medicinal chemistry team engineers ligands with binding constants in the sub-nanomolar range. Each ligand undergoes rigorous selectivity screening against a panel of off-target receptors to confirm specificity. The result is a molecular key that fits only the diseased cell's lock.
Therapeutic payloads — ranging from cytotoxic small molecules to gene-silencing oligonucleotides — are conjugated to the ligand via proprietary cleavable linker chemistry. Linkers are designed to remain stable in circulation but undergo rapid hydrolysis or enzymatic cleavage upon internalization into the target cell's endosomal compartment, releasing the active payload intracellularly.
Neologicals conjugates circulate systemically but accumulate preferentially at sites of receptor overexpression. Upon receptor binding, the conjugate is internalized via receptor-mediated endocytosis. Intracellular payload release achieves cytotoxic concentrations within the target cell while systemic exposure remains orders of magnitude below toxic thresholds.
Evidence-Backed Performance
Neologicals-001, our lead EGFR-targeting conjugate, has demonstrated compelling efficacy and tolerability in multiple preclinical models. Key findings from our IND-enabling studies:
Why Neologicals Outperforms Existing Approaches
| Category | Neologicals Platform | Conventional Approach |
|---|---|---|
| Targeting Mechanism | Active receptor-mediated targeting | Passive EPR effect / systemic distribution |
| Binding Specificity | Sub-nanomolar, receptor-selective | Broad biodistribution, non-selective |
| Payload Release | Intracellular, triggered by endosomal conditions | Systemic release, pH/time-dependent |
| Therapeutic Index | 3x broader — higher efficacy at lower systemic dose | Narrow — dose-limiting toxicity constrains efficacy |
| Platform Modularity | Payload-agnostic, multi-indication capable | Single modality, indication-specific |
One Platform. Multiple Indications.
The modular architecture of Neologicals enables rapid adaptation to new targets and indications. Current programs span oncology and inflammatory disease, with a pipeline designed to validate the platform across diverse receptor biology.
Solid Tumors
EGFR, HER2, and mesothelin-overexpressing cancers represent the initial oncology focus, with Neologicals-001 in Phase I/II for advanced solid tumors.
Hematologic Malignancies
CD22-targeted delivery to B-cell malignancies, including Non-Hodgkin Lymphoma, leverages the platform's precision in a highly receptor-defined cell population.
Inflammatory Disease
Synovial macrophage targeting in Rheumatoid Arthritis demonstrates the platform's applicability beyond oncology — precision delivery to inflammatory lesions.
Explore the Science Behind Neologicals
Our scientific team is available to discuss the platform in depth with qualified investors, research partners, and clinical collaborators.